SCHEMBL10206633

SCHEMBL10206633

CC1(C)C(=O)Nc2cccc(CNc3nc(Nc4ccc(C5CCN(CCO)CC5)cc4)ncc3Cl)c21

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 3/20 0.46
▸ STAT6 P42226 1/20 0.45
▸ FLT4 P35916 1/20 0.44
▸ KDR P35968 1/20 0.44
▸ STK17A Q9UEE5 1/20 0.43
▸ TNK2 Q07912 2/20 0.43
▸ AXL P30530 2/20 0.42
▸ JAK3 P52333 2/20 0.42
▸ NTRK1 P04629 4/20 0.42
▸ KCNH2 Q12809 1/20 0.41
▸ WEE1 P30291 1/20 0.40
▸ TYRO3 Q06418 1/20 0.40
▸ MERTK Q12866 1/20 0.40
▸ CSF1R P07333 1/20 0.40
▸ MAP4K1 Q92918 1/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ JAK1 P23458 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10205202 0.92 JAK3 (0.40) EGFRSTAT6FLT4KDRSTK17A
SCHEMBL10206634 0.92 STAT6 (0.44) EGFRSTAT6FLT4KDRTNK2
SCHEMBL10206199 0.92 STK17A (0.46) EGFRSTAT6FLT4KDRSTK17A
SCHEMBL10206622 0.91 ALK (0.44) EGFRSTAT6FLT4KDRSTK17A
SCHEMBL10206626 0.91 STK17A (0.42) EGFRSTAT6FLT4KDRSTK17A
SCHEMBL14331630 0.91 STK17A (0.42) EGFRSTAT6FLT4KDRSTK17A
SCHEMBL14331681 0.90 STK17A (0.42) STAT6FLT4KDRSTK17ATNK2
SCHEMBL10205190 0.89 EGFR (0.51) EGFRFLT4TNK2JAK3KCNH2
SCHEMBL10206621 0.89 JAK3 (0.43) EGFRSTAT6FLT4KDRSTK17A
SCHEMBL10205122 0.87 STK17A (0.46) EGFRSTAT6FLT4KDRSTK17A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655358-B1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-11-19 — — EP disclosed
US-8546443-B2 Benzylic oxindole pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 — — US disclosed
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-27 — — US disclosed
WO-2012085126-A1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES MKI67, CCNI, CCNB1 EGFR 1397/4885STAT6 1155/4885FLT4 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback